Theseus Pharmaceuticals
  • Contact
  • Company
    • About Us
    • Leadership
    • Contact
  • Science
    • Our Approach
    • Disease Focus
    • Publications & Posters
  • Pipeline
    • Pipeline
    • KIT Program for GIST
    • EGFR Program for NSCLC
    • Discovery Program
    • Expanded Access Policy
  • Join Us
    • Our Culture
    • Open Roles
    • Diversity Commitment
  • Investors & Media
    • Corporate Profile
    • News & Events
      • News Releases
      • Events
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
    • SEC Filings
    • Corporate Governance
      • Corporate Governance
      • Leadership Team
      • Board of Directors
      • Board Committees
    • Investor Resources
      • Investor FAQs
      • Investor Alerts
Select Page
Theseus Pharmaceuticals
    • Company
      • About Us
      • Leadership
      • Contact
    • Science
      • Our Approach
      • Disease Focus
      • Publications & Posters
    • Pipeline
      • Pipeline
      • KIT Program for GIST
      • EGFR Program for NSCLC
      • Discovery Program
      • Expanded Access Policy
    • Join Us
      • Our Culture
      • Open Roles
      • Diversity Commitment
    • Investors & Media
      • Corporate Profile
      • News & Events
        • News Releases
        • Events
      • Stock Information
        • Stock Quote & Chart
        • Historical Price Lookup
      • SEC Filings
      • Corporate Governance
        • Corporate Governance
        • Leadership Team
        • Board of Directors
        • Board Committees
      • Investor Resources
        • Investor FAQs
        • Investor Alerts
Header_Image_Investors
SEC Filings
Theseus Pharmaceuticals
YearTrailing 12-MonthsCalendar Year 2023Calendar Year 2022Calendar Year 2021Calendar Year 2018
ViewAll FilingsAnnual FilingsQuarterly FilingsCurrent FilingsRegistration StatementsSection 16Proxy & Information StatementsOther
FormDescriptionDateFormat
ARSAn annual report to security holders.Apr 26, 2023Open An annual report to security holders. in HTML.Open An annual report to security holders. in DOC file.Open An annual report to security holders. in PDF file.Open An annual report to security holders. in XLS file.
10-KAnnual report which provides a comprehensive overview of the company for the past yearMar 9, 2023Open Annual report which provides a comprehensive overview of the company for the past year in HTML.Open Annual report which provides a comprehensive overview of the company for the past year in DOC file.Open Annual report which provides a comprehensive overview of the company for the past year in PDF file.Open Annual report which provides a comprehensive overview of the company for the past year in XLS file.Open Annual report which provides a comprehensive overview of the company for the past year in XBLR Viewer.Open Annual report which provides a comprehensive overview of the company for the past year in XBLR file.

Investor Contact

Josh Rappaport
Stern Investor Relations
212-362-1200
josh.rappaport@sternir.com

Footer logo

Company

  • About Us
  • Leadership
  • Contact

Science

  • Our Approach
  • Disease Focus
  • Publications & Posters

Programs

  • Pipeline
  • KIT Program
  • EGFR Program
  • Discovery Program
  • Expanded Access Policy

Join Us

  • Our Culture
  • Open Roles
  • Diversity Commitment

Investors

  • Corporate Profile
  • News & Events
  • Stock Information
  • SEC Filings
  • Corporate Governance
  • Resources
Footer logo
© 2023 Theseus Pharmaceuticals. All rights reserved.
  • Privacy Policy
  • Terms of Use